2/19
10:01 am
vstm
Verastem (NASDAQ:VSTM) was given a new $18.00 price target on by analysts at Mizuho.
Low
Report
Verastem (NASDAQ:VSTM) was given a new $18.00 price target on by analysts at Mizuho.
2/18
07:30 am
vstm
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Medium
Report
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
2/4
08:42 am
vstm
Verastem (NASDAQ:VSTM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
Medium
Report
Verastem (NASDAQ:VSTM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
2/4
07:30 am
vstm
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
Medium
Report
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
1/12
04:01 pm
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/30
03:38 pm
vstm
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]
Neutral
Report
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]
12/30
07:17 am
vstm
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/29
04:01 pm
vstm
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Medium
Report
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
12/15
04:45 pm
vstm
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]
Medium
Report
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]
12/15
04:01 pm
vstm
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Medium
Report
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
12/15
09:43 am
vstm
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]
Medium
Report
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]
11/25
07:30 am
vstm
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Medium
Report
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference